The development of immuno-oncology (IO) therapeutics has changed the way we treat many cancers, most dramatically with inhibitors of programmed cell death-1 (PD-1), its ligand (PD-L1) and cytotoxic T-lymphocyte-associated antigen (CTLA-4) (2–4). Here, PDCD1 is linked to cancer.